Skip to main navigation Skip to search Skip to main content

Evaluation of myocardial viability with thallium-201 infusion MPSPECT after oral glucose application in patients with chronic coronary artery disease

  • Zekiye Hasbek
  • , Bulent Turgut*
  • , Taner Erselcan
  • , Kenan Yalta
  • , Izzet Tandogan
  • , Gurkan Ozer
  • , Umit Ozdemir
  • , Nergiz Hacer Turgut
  • *Corresponding author for this work
  • Ministry of Health
  • School of Medicine
  • Cumhuriyet University
  • School of Medicine

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Aim: The aim of this study was to evaluate the myocardial viability in nondiabetic patients with chronic coronary artery disease (CCAD) or past myocardial infarction (MI), using thallium-201 infusion myocardial perfusion single-photon emission computed tomography (MPSPECT) imaging after oral glucose application (Glu+Tl-infusion). Materials and Methods: In this study, 33 nondiabetic patients (three female, 30 male, mean age: 55.24±11years, range: 33-77 years) with MI history or known CCAD were included. Rest/redistribution/24h-late-MPSPECT imaging was performed for all patients. In all patients in whom fixed perfusion defect was observed on any wall of the left ventriculi, after 24h-late-MPSPECT imaging, 75g oral glucose was given. Thirty minutes later, 1 mCi thallium-201 in 100 ml of physiological saline solution was applied in a period of 20 min by slow infusion. After infusion at the 10th minute, MPSPECT imaging was performed. Perfusion was evaluated visually for a total of 3432 segments with the 26-segment 5-point scoring technique. Scoring measured perfusion as 0=no perfusion defect, 1=mildly reduced, 2=moderately reduced, 3=severely reduced, and 4=absent uptake. Scores '0 and 1' were considered normal and scores '2-4' were considered abnormal. Results: For serum insulin levels measured after glucose application, a significant increase was determined, according to the period before glucose application (P<0.001). When compared with rest MPSPECT images, segmental perfusion improvement both in redistribution and in the 24h-late-MPSPECT images were 16.3 and 18.3%, respectively. This ratio was found to be 27.2% for Glu+Tl-infusion images. The ratios of segments in which perfusion was worsening were calculated to be 9.4, 14.5, and 7.3%, respectively, for redistribution, 24h-late-MPSPECT, and Glu+Tl-infusion images. When this evaluation was made for all three vessel areas, again the highest perfusion improvement and the lowest perfusion worsening were detected for Glu+Tl-infusion images. In addition, when this evaluation was made for the three vessel areas according to the coronary narrowing degree, again the highest perfusion improvement was detected for Glu+Tl-infusion images, in segments in the left anterior descending artery, and right coronary artery areas with ≥90% narrowing. In rest images, in segments with segmental scores of 3 and 4, when the total reversibility ratio was evaluated, this ratio was calculated to be 0.7% for redistribution images and 4.5% for 24h-late-MPSPECT. The highest total reversibility ratio in these segments was detected with Glu+Tl-infusion images to be 10.3%. When we evaluated the patients with respect to the MI history time, the highest segmental perfusion improvement was detected in patients with 0-3 months of MI history. Conclusion: We conclude that in nondiabetic patients who are known to have CCAD or past MI history, Glu+Tl-infusion is an easily applicable method that gives better results for the evaluation of myocardial viability.

Original languageEnglish
Pages (from-to)779-788
Number of pages10
JournalNuclear Medicine Communications
Volume30
Issue number10
DOIs
StatePublished - Oct 2009
Externally publishedYes

Keywords

  • Chronic coronary artery disease
  • Myocardial perfusion single-photon emission computed tomography
  • Myocardial viability
  • Oral glucose
  • Thallium-201 infusion

Fingerprint

Dive into the research topics of 'Evaluation of myocardial viability with thallium-201 infusion MPSPECT after oral glucose application in patients with chronic coronary artery disease'. Together they form a unique fingerprint.

Cite this